Markus P Schlaich
Overview
Explore the profile of Markus P Schlaich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
326
Citations
6405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flack J, Schlaich M, Weber M, Sassi-Sayadi M, Narkiewicz K, Clozel M, et al.
Hypertension
. 2025 Jan;
PMID: 39840441
Background: Black individuals frequently present with resistant hypertension and disproportionately increased cardiovascular risk. We investigated the blood pressure (BP)-lowering effect of the dual endothelin receptor antagonist aprocitentan in Black individuals...
2.
Chia Y, He F, Cheng M, Shin J, Cheng H, Sukonthasarn A, et al.
Hypertens Res
. 2024 Oct;
48(1):301-313.
PMID: 39472546
Cardiovascular diseases (CVD) continue to be the leading cause of deaths and disability worldwide and the major contributor is hypertension. Despite all the improvements in detecting hypertension together with technological...
3.
OHagan E, Marschner S, Mishra S, Min H, Schutte A, Schlaich M, et al.
Hypertension
. 2024 Oct;
81(12):2559-2568.
PMID: 39450502
Background: Community-based health check kiosks provide opportunities to improve the detection and long-term monitoring of hypertension. We describe the sociodemographic and cardiovascular characteristics of first-time and repeat users of these...
4.
Rodgers A, Salam A, Schutte A, Cushman W, de Silva H, Di Tanna G, et al.
Lancet
. 2024 Oct;
404(10462):1536-1546.
PMID: 39426836
Background: Single-pill combinations (SPCs) of three low-dose antihypertensive drugs can improve hypertension control but are not widely available. A key issue for any combination product is the contribution of each...
5.
Radavelli-Bagatini S, Bondonno C, Dalla Via J, Sim M, Gebre A, Blekkenhorst L, et al.
Nat Commun
. 2024 Oct;
15(1):8126.
PMID: 39402045
Provision of non-invasive vascular imaging results to individuals has been shown to improve cardiovascular disease risk factor control: its impact on diet remains uncertain. In this two-arm, single-blind, parallel, 12-week...
6.
Ananda R, Gwini S, Beilin L, Schlaich M, Stowasser M, Young M, et al.
Circulation
. 2024 Oct;
150(25):2019-2030.
PMID: 39351674
Background: Primary aldosteronism, characterized by renin-independent aldosterone production, is associated with adverse cardiovascular remodeling and outcomes. Elevated cardiovascular risk is observed even in subclinical forms of primary aldosteronism according to...
7.
Rodgers A, Salam A, Schutte A, Cushman W, de Silva H, Di Tanna G, et al.
J Am Coll Cardiol
. 2024 Sep;
84(24):2393-2403.
PMID: 39217570
Background: Single-pill combinations of 3 or more low-dose blood pressure (BP)-lowering drugs hold promise for initial or early treatment of hypertension. Objectives: The authors conducted a placebo-controlled trial of a...
8.
Nolde J, Beaney T, Carnagarin R, Stergiou G, Poulter N, Schutte A, et al.
Hypertension
. 2024 Aug;
81(10):2091-2100.
PMID: 39109449
Background: The strong relationship between blood pressure (BP) and age is well known. Limited evidence suggests that a steeper age-BP slope may be associated with an increased risk of adverse...
9.
Matthews J, Herat L, Schlaich M, Matthews V
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062029
The hyperactivation of the sympathetic nervous system (SNS) is linked to obesity, hypertension, and type 2 diabetes, which are characterized by elevated norepinephrine (NE) levels. Previous research has shown increased...
10.
Poulter N, Schlaich M, Schutte A, Stergiou G, Kiru G, McArdle H, et al.
Eur Heart J Suppl
. 2024 Jul;
26(Suppl 3):iii1-iii4.
PMID: 39055594
No abstract available.